絞り込み

16645

広告

新型肺炎 空港や港の検疫所でもウイルス検査実施へ 厚労省

中国で新型コロナウイルスによる肺炎が拡大する中、厚生労働省は感染者をより早期に発見するため、空港や港にある検疫所でもウイルス検査を実施していくことになりました。...

  1. 「クイーン」のブライアン・メイさん 京都...
  2. 新型肺炎「指定感染症」に きょう閣議決定...
  3. ルマテペロンは統合失調症の症状を軽減 (...
  4. 「嘔吐後の肺炎=誤嚥性肺炎」ではない! ...

ニュース一覧

Generation and Immunogenicity of a Recombinant Pseudorabies Virus Co-Expressing Classical Swine Fever Virus E2 Protein and Porcine Circovirus Type 2 Capsid Protein Based on Fosmid Library Platform.

著者 Abid M , Teklue T , Li Y , Wu H , Wang T , Qiu HJ , Sun Y
Pathogens.2019 Dec 01 ; 8(4):.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (3view , 0users)

Full Text Sources

Miscellaneous

Pseudorabies (PR), classical swine fever (CSF), and porcine circovirus type 2 (PCV2)-associated disease (PCVAD) are economically important infectious diseases of pigs. Co-infections of these diseases often occur in the field, posing significant threat to the swine industry worldwide. gE/gI/TK-gene-deleted vaccines are safe and capable of providing full protection against PR. Classical swine fever virus (CSFV) E2 glycoprotein is mainly used in the development of CSF vaccines. PCV2 capsid (Cap) protein is the major antigen targeted for developing PCV2 subunit vaccines. Multivalent vaccines, and especially virus-vectored vaccines expressing foreign proteins, are attractive strategies to fight co-infections for various swine diseases. The gene-deleted pseudorabies virus (PRV) can be used to develop promising and economical multivalent live virus-vectored vaccines. Herein, we constructed a gE/gI/TK-gene-deleted PRV co-expressing E2 of CSFV and Cap of PCV2 by fosmid library platform established for PRV, and the expression of E2 and Cap proteins was confirmed using immunofluorescence assay and western blotting. The recombinant virus propagated in porcine kidney 15 (PK-15) cells for 20 passages was genetically stable. The evaluation results in rabbits and pigs demonstrate that rPRVTJ-delgE/gI/TK-E2-Cap elicited detectable anti-PRV antibodies, but not anti-PCV2 or anti-CSFV antibodies. These findings provide insights that rPRVTJ-delgE/gI/TK-E2-Cap needs to be optimally engineered as a promising trivalent vaccine candidate against PRV, PCV2 and CSFV co-infections in future.
PMID: 31805703 [PubMed]
印刷用ページを開く Endnote用テキストダウンロード